Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Myeloid 2

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3Thrombocythemia, Essential 2Polycythemia Vera 2Skin Neoplasms 1Philadelphia Chromosome 1Neoplasm, Residual 1Neoplasm Metastasis 1Myeloproliferative Disorders 1Melanoma 1Leukemia, Myeloid, Acute 1Leukemia 1Infections 1Hepatitis C 1Glioma 1Carcinoma, Squamous Cell 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1Brain Neoplasms 1

Interventions

fludarabine phosphate 18Whole-Body Irradiation 12Peripheral Blood Stem Cell Transplantation 12Mycophenolic Acid 11ruxolitinib 10Busulfan 10Tacrolimus 9Cyclophosphamide 9fludarabine 6Methotrexate 5Melphalan 5Cyclosporine 5Hydroxyurea 4Antilymphocyte Serum 4pomalidomide 3givinostat hydrochloride 3givinostat 3Stem Cell Transplantation 3Prednisone 3Lenalidomide 311-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 3thymoglobulin 2peginterferon alfa-2a 2merphos 2Surveys and Questionnaires 2Radiotherapy 2Imatinib Mesylate 2Etoposide 2Dasatinib 2Carboplatin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Polycythemia Vera × peginterferon alfa-2a × Clear all
NCT00452023 2024-12-11

Pegasys® in Patients With Myeloproliferative Diseases

M.D. Anderson Cancer Center

Phase 2 Completed
83 enrolled 12 charts
Myeloid

Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential

NCT01259856 2019-04-30

Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET)

Icahn School of Medicine at Mount Sinai

Phase 3 Completed
168 enrolled 16 charts
Myeloid

Polycythemia Vera, Thrombocythemia, Essential

Data powered by HemOnc (CC BY 4.0) Colophon âš¡